Bristol-Myers Squibb Company (NYSE:BMY) announced that 20 abstracts for Orencia® (abatacept), and clazakizumab have been accepted for presentation at the 2014 annual meeting of the European League Against Rheumatism (EULAR), to be held June 11-14 in Paris, France. Bristol-Myers Squibb Co (NYSE:BMY) net profit margin is 17.70% and weekly performance is -0.27%. On last trading day company shares ended up $48.80. Analysts mean target price for the company is $54.76. Bristol-Myers Squibb Co (NYSE:BMY) distance from 50-day simple moving average (SMA50) is -4.05%.
Eli Lilly and Company (NYSE:LLY) will attend the 30(th) Annual Sanford C. Bernstein Strategic Decisions Conference on Wednesday, May 28, 2014. John C. Lechleiter, Ph.D., Lilly’s chairman, president and chief executive officer, will participate in a fireside chat at 3:00 p.m. EDT. Eli Lilly and Co (NYSE:LLY) shares advanced 1.10% in last trading session and ended the day on $59.72. LLY gross Margin is 77.60% and its return on assets is 11.30%.Eli Lilly and Co (NYSE:LLY) quarterly performance is 3.90%.
Gilead Sciences, Inc. (NASDAQ:GILD) recently reported much encouraging clinical findings from Phase IIa study concerning the company’s pipeline molecule GS-5806. Gilead Sciences, Inc. (NASDAQ:GILD) shares moved up 1.33% in last trading session and was closed at $82.90, while trading in range of $81.56 – $83.70. Gilead Sciences, Inc. (NASDAQ:GILD) year to date (YTD) performance is 10.39%.
Biogen Idec Inc. (NASDAQ:BIIB) announced that it will present at the Sanford Bernstein 30th Annual Strategic Decisions Conference. The webcast will be live on Wednesday, May 28, 2014 at 2:00 p.m. ET. Biogen Idec Inc. (NASDAQ:BIIB) ended the last trading day at $299.69. Company weekly volatility is calculated as 2.49% and price to cash ratio as 56.41.Biogen Idec Inc. (NASDAQ:BIIB) showed a positive weekly performance of 3.51%.
Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) announced on 20 may the establishment of a strategic alliance with Pathology, Inc. in Torrance, Calif., that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years. On last trading day company shares ended up $37.52.
Leave a Reply